• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cue Biopharma Inc.

    3/31/25 4:09:38 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUE alert in real time by email
    S-8 1 s-8_evergreen_shares_202.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 31, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Cue Biopharma, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

    Delaware

    47-3324577

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

    40 Guest Street

    Boston, MA

    02135

    (Address of principal executive offices)

    (Zip Code)

    2016 Omnibus Incentive Plan, as amended

    Inducement Stock Option Award (November 25, 2024)

    (Full title of the plan)

    Daniel R. Passeri

    Chief Executive Officer

    Cue Biopharma, Inc.

    40 Guest Street

    Boston, MA 02135

    (Name and address of agent for service)

    (617) 949-2680

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.

    The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”) and the Note to Part I of Form S-8.

    Item 2. Registrant Information and Employee Plan Annual Information.

    The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.

     

     


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

    (a)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 31, 2025;
    (b)
    The Registrant’s Current Report on Form 8-K as filed with the Commission on March 12, 2025; and
    (c)
    The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A, as filed with the Commission on December 13, 2017, as the description therein has been updated and superseded by the description of the Registrant’s capital stock contained in Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 31, 2025, and including any amendments and reports filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    The following summary is qualified in its entirety by reference to the complete Delaware General Corporation Law (the “DGCL”) and the Registrant’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and the Registrant’s Amended and Restated Bylaws.

    Section 145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably

     


     

    believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

    Section 102(b)(7) of the DGCL provides, generally, that the Certificate of Incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision may not eliminate or limit the liability of (i) a director or officer for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) a director under section 174 of the DGCL, (iv) a director or officer for any transaction from which the director or officer derived an improper personal benefit, or (v) an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective.

    Article VI of the Certificate of Incorporation states that the Registrant’s directors shall not be personally liable to the Registrant or to its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. Under Section 102(b)(7) of the DGCL, the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty can be limited or eliminated except (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under Section 174 of the DGCL (relating to unlawful payment of dividend or unlawful stock purchase or redemption); or (iv) for any transaction from which the director derived an improper personal benefit.

    Article V of the Certificate of Incorporation provides that the Registrant shall indemnify (and advance expenses to) its officers and directors to the full extent permitted by the DGCL.

    The Registrant has directors’ and officers’ liability insurance insuring its directors and officers against liability for acts or omissions in their capacities as directors or officers, subject to certain exclusions. Such insurance also insures the Registrant against losses which it may incur in indemnifying its officers and directors. As permitted by the DGCL, the Registrant has entered into indemnification agreements with each of its directors and executive officers that require the Registrant to indemnify such persons against various actions including, but not limited to, third-party actions where such director or executive officer, by reason of his or her corporate status, is a party or is threatened to be made a party to an action, or by reason of anything done or not done by such director in any such capacity. The Registrant intends to indemnify directors and executive officers against all costs, judgments, penalties, fines, liabilities, amounts paid in settlement by or on behalf of such directors or executive officers and for any expenses actually and reasonably incurred by such directors or executive officers in connection with such action, if such directors or executive officers acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the Registrant, and with respect to any criminal proceeding, had no reasonable cause to believe their conduct was unlawful. The Registrant also intends to advance to its directors and executive officers’ expenses (including attorney’s fees) incurred by such directors and executive officers in advance of the final disposition of any action after the receipt by the Registrant of a statement or statements from directors or executive officers requesting such payment or payments from time to time, provided that such statement or statements are accompanied by an undertaking, by or on behalf of such directors or executive officers, to repay such amount if it shall ultimately be determined that they are not entitled to be indemnified against such expenses by the Registrant.

    The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification or advancement of expenses, including, among others, provisions about providing notice to the Registrant of any action in connection with which a director or executive officer seeks indemnification or advancement of expenses from the Registrant and provisions concerning the determination of entitlement to indemnification or advancement of expenses.

     

     


     

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The following exhibits are incorporated herein by reference:

     

     

     

    Number

    Description

     

     

      4.1

    Amended and Restated Certificate of Incorporation, as amended, of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38327) filed with the Securities and Exchange Commission on November 14, 2024)

     

     

      4.2

    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-220550) filed with the Securities and Exchange Commission on December 5, 2017)

     

     

      5.1*

    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

     

     

    23.1*

    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)

     

     

    23.2*

    Consent of RSM US LLP, Independent Registered Public Accounting Firm

     

     

    24.1*

    Power of attorney (included on the signature pages of this registration statement)

     

     

    99.1

    Cue Biopharma, Inc. 2016 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.13 to the Registrant’s Registration Statement on Form S-1 (File No. 333-220550) filed with the Securities and Exchange Commission on September 21, 2017)

     

     

    99.2

     

    Amendment No. 1 to Cue Biopharma, Inc. 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K (File No. 001-38327) filed with the Securities and Exchange Commission on March 12, 2020)

     

     

    99.3

    Amendment No. 2 to Cue Biopharma, Inc. 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38327) filed with the Securities and Exchange Commission on August 8, 2023)

     

     

     

    99.4

     

    Form of Inducement Stock Option Award (incorporated by reference to Exhibit 10.43 to the Registrant’s Annual Report on Form 10-K (File No. 001-38327) filed with the Securities and Exchange Commission on March 31, 2025)

     

     

     

    107*

     

    Calculation of Filing Fee Tables

     

     

     

     

    * Filed herewith.

     


     

    Item 9. Undertakings.

    1.
    The undersigned registrant hereby undertakes:
    a.
    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
    i.
    To include any prospectus required by Section 10(a)(3) of the Securities Act;
    ii.
    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective registration statement; and
    iii.
    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

    b.
    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    c.
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    2.
    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    3.
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 31st day of March, 2025.

     

     

     

    CUE BIOPHARMA, INC.

     

     

    By:

    /s/ Daniel R. Passeri

     

    Daniel R. Passeri

     

    Chief Executive Officer

     

     


     

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Cue Biopharma, Inc., hereby severally constitute and appoint Daniel R. Passeri, Kerri-Ann Millar and Colin Sandercock, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Cue Biopharma, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ Daniel R. Passeri

    Daniel R. Passeri

    Chief Executive Officer and

    Director

    (Principal executive officer)

    March 31, 2025

     

     

     

    /s/ Kerri-Ann Millar

    Kerri-Ann Millar

    Chief Financial Officer

    (Principal financial and

    accounting officer)

    March 31, 2025

     

     

     

    /s/ Frederick Driscoll

    Frederick Driscoll

    Director

    March 31, 2025

     

     

     

    /s/ Pamela Garzone

    Pamela Garzone

    Director

    March 31, 2025

     

     

     

     

     

    /s/ Patrick Verheyen

     

    Director

     

    March 31, 2025

    Patrick Verheyen

     

     

     

     

     

     

     

     

    /s/ Peter Kiener

     

    Director

     

    March 31, 2025

    Peter Kiener

     

     

     

     

     

     

     

     

    /s/ Frank Morich

     

    Director

     

    March 31, 2025

    Frank Morich

     

     

     

     

     

     

     

     

    /s/ Pasha Sarraf

     

    Director

     

    March 31, 2025

    Pasha Sarraf

     

     

     

     

     

     

     

     

     

     


    Get the next $CUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CUE

    DatePrice TargetRatingAnalyst
    3/13/2024$6.00Buy
    Jefferies
    6/26/2023$10.00Outperform
    Oppenheimer
    11/21/2022$7.00Overweight
    Piper Sandler
    1/13/2022$20.00Buy
    H.C. Wainwright
    1/3/2022$28.00Buy
    Craig Hallum
    More analyst ratings

    $CUE
    Financials

    Live finance-specific insights

    See more
    • Cue Biopharma to Host Business Update Call and Webcast

      BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1-844-826-3035International Investors:1-412-317-5195Conference ID:10199037Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 The live and archived webcast will also b

      4/14/25 5:02:00 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma to Host Business Update Call and Webcast

      BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company's approach to enhance near-term shareholder value by refocusing resourc

      8/13/24 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma to Host Business Update Call and Webcast

      BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional au

      4/2/24 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Millar Kerri-Ann

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      3/25/25 4:00:10 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Baker Daniel G.

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      3/25/25 4:00:07 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Passeri Daniel R

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      3/25/25 4:00:09 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cue Biopharma to Host Virtual Investor Event on May 15, 2025

      Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will host a virtual investor event on Thursday, May 15, 2025 at 11:00 AM ET. To register, click here. The virtual event will feature key opinion leaders (KOLs) Richard DiPaolo, PhD (Saint Louis University) and And

      5/8/25 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

      BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in New York, May 7-8, 2025. During the fireside chat, Cue Biopharma will discuss progress on its programs from the Immuno-STAT™ platform including the CUE-100 series, CUE-401, and CUE-501, which was recently partnered with Boehringer Ingelheim for T cell mediated targeted depletion of specific B cells to

      5/5/25 10:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

      BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase an aggregate of 2,867,304 shares of

      4/14/25 10:23:10 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Cue Biopharma with a new price target

      Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00

      3/13/24 7:30:48 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Cue Biopharma with a new price target

      Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00

      6/26/23 7:24:09 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Cue Biopharma with a new price target

      Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00

      11/21/22 7:39:31 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

      BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO). With an extensive background and proven expertise in strategic transactions, portfolio optimization and alliance management through her extensive tenure at Johnson & Johnson and Jansen, Ms. Warren will play a pivotal role in advancing Cue Biopharma's core corporate objectives following the company's recent business restructuring and autoimmune program prioritizati

      9/9/24 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

      BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in drug development, including strategic, scientific, clinical and regulatory leadership expertise. "We are pleased to have Dr. Garzone join our board of directors," said Daniel Passeri, chief executive

      4/25/23 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

      BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD). Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson. "We are very pleased to welcome Mr. Verheyen to our BOD and leverage his extensive experience and guidance as we seek to enhance and broaden Cue Bi

      4/12/23 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cue Biopharma Inc.

      SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

      3/11/24 6:40:41 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cue Biopharma Inc.

      SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

      2/7/24 5:09:04 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cue Biopharma Inc.

      SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

      1/31/24 2:08:28 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Cue Biopharma Inc.

      DEF 14A - Cue Biopharma, Inc. (0001645460) (Filer)

      4/25/25 4:00:15 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Cue Biopharma Inc.

      DEFA14A - Cue Biopharma, Inc. (0001645460) (Filer)

      4/25/25 4:00:03 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Cue Biopharma Inc.

      8-K - Cue Biopharma, Inc. (0001645460) (Filer)

      4/15/25 4:48:23 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Passeri Daniel R bought $30,900 worth of shares (30,000 units at $1.03), increasing direct ownership by 22% to 164,578 units (SEC Form 4)

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      12/18/24 4:00:04 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care